ALT · NASDAQ
Altimmune (ALT) Stock Price & Fundamentals
Altimmune (ALT) closed at $505.51 on Oct 9, 2026, up 0.49% from the previous close of $503.05.
Share price, past year
1Y +11.84%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $505.51 |
| Sep 30, 2026 | $508.54 |
| Aug 31, 2026 | $525.83 |
| Jul 31, 2026 | $533.21 |
| Jun 30, 2026 | $527.12 |
| May 29, 2026 | $519.73 |
| Apr 30, 2026 | $513.04 |
| Mar 31, 2026 | $515.94 |
| Feb 27, 2026 | $493.97 |
| Jan 30, 2026 | $480.51 |
| Dec 31, 2025 | $488.22 |
| Nov 28, 2025 | $439.16 |
| Oct 31, 2025 | $447.19 |
Key statistics
- Market cap
- $98.31B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.77
- Revenue (TTM)
- $41.00K
- Net income (TTM)
- −$91.76M
- Shares outstanding
- 194.5M
- Dividend yield
- —
- 52-week range
- $434.44 – $540.13
Altimmune's market cap is $98.31B, based on a share price of $505.51 and 194.5M shares outstanding as of Jun 30, 2026.
Financials
Altimmune reported revenue of $41.00K for fiscal 2025, up 105.00% from fiscal 2024.
Altimmune reported a net loss of $88.09M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $41.00K | +105.0% | −$88.09M | −214,861.0% | −$1.00 | −$67.55M |
| FY2024ended Dec 31, 2024 | $20.00K | −95.3% | −$95.06M | −475,295.0% | −$1.34 | — |
| FY2023ended Dec 31, 2023 | $426.00K | +726.5% | −$88.45M | −20,762.2% | −$1.66 | −$75.86M |
| FY2022ended Dec 31, 2022 | −$68.00K | −101.5% | −$84.71M | 124,577.9% | −$1.81 | −$62.71M |
| FY2021ended Dec 31, 2021 | $4.41M | −46.1% | −$97.09M | −2,201.6% | −$2.35 | −$90.36M |
| FY2020ended Dec 31, 2020 | $8.19M | +41.1% | −$49.04M | −599.2% | −$1.91 | −$34.51M |
| FY2019ended Dec 31, 2019 | $5.80M | −43.9% | −$20.52M | −353.7% | −$1.60 | −$9.60M |
| FY2018ended Dec 31, 2018 | $10.33M | −3.8% | −$39.17M | −379.2% | −$15.16 | −$10.36M |
| FY2017ended Dec 31, 2017 | $10.74M | +231.8% | −$46.43M | −432.3% | −$118.91 | −$20.33M |
| FY2016ended Dec 31, 2016 | $3.24M | — | −$11.09M | −342.6% | $2.95 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2025ended Dec 31, 2025 | $26.00K | −$27.36M | −$0.26 |
| Q3 FY2025ended Sep 30, 2025 | $5.00K | −$19.01M | −$0.21 |
| Q2 FY2025ended Jun 30, 2025 | $5.00K | −$22.15M | −$0.27 |
| Q1 FY2025ended Mar 31, 2025 | $5.00K | −$19.58M | −$0.26 |
| Q4 FY2024ended Dec 31, 2024 | $5.00K | −$23.18M | −$0.33 |
| Q3 FY2024ended Sep 30, 2024 | $5.00K | −$22.85M | −$0.32 |
| Q2 FY2024ended Jun 30, 2024 | $5.00K | — | — |
| Q1 FY2024ended Mar 31, 2024 | $5.00K | — | — |
Company profile
- Name
- Altimmune, Inc.
- Ticker
- ALT
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 910 Clopper Road, Suite 201s, Gaithersburg, MD 20878
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001326190
Recent SEC filings
- Sep 29, 2026
- Aug 12, 2026
- Aug 12, 2026
- Jul 28, 2026
- Jun 16, 2026
- May 13, 2026
- May 13, 2026
- Apr 24, 2026
Frequently asked questions
What is Altimmune's stock price?
Altimmune (ALT) closed at $505.51 on Oct 9, 2026, up 0.49% from the previous close of $503.05.
What is Altimmune's market cap?
Altimmune's market cap is $98.31B, based on a share price of $505.51 and 194.5M shares outstanding as of Jun 30, 2026.
How much revenue does Altimmune make?
Altimmune reported revenue of $41.00K for fiscal 2025, up 105.00% from fiscal 2024.
Does Altimmune pay a dividend?
Altimmune's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Altimmune, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures